Contact Congress about H.R. 6214: Kidney Care Access Protection Act

People on dialysis could get better access to some newer drugs and devices. Medicare would give extra payments for these products and add kidney screening to yearly wellness visits starting in 2026.

Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Kidney Care Access Protection Act is a House bill in committee. The latest recorded action: Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Latest action on H.R. 6214: Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Who this affects: This bill mainly affects people with kidney failure who rely on Medicare for dialysis and related care. It also affects dialysis clinics, Medicare Advantage plans, clinicians who teach patients about kidney disease, and Medicare officials who set payment rules.

Why this matters: Kidney failure care is expensive, and payment rules can shape which treatments clinics offer. This bill could help newer dialysis drugs and devices reach patients sooner by paying extra for them. It could also help more people learn about kidney disease earlier through screening and education. The bill may raise Medicare spending, but it does not say how much.

Key provisions in H.R. 6214

• Medicare would give longer extra payment support for eligible new dialysis drugs and devices. The support would last at least three years for items provided on or after January 1, 2026.
• Many new dialysis drugs and biological products would get an ongoing extra payment after the temporary drug add-on ends. This would apply to products used on or after January 1, 2026.
• Medicare would use recent use and price data to set the ongoing extra payment. If needed, it could use the wholesale purchase price or a manufacturer invoice, divide by the number of dialysis treatments, pay 65% of that amount, and update it each year for inflation.
• The ongoing extra payment for innovative drugs would add money to the kidney payment system. Medicare would not have to offset it with cuts elsewhere, and patient case-mix factors would not change it.
• Some newer drugs for other health problems would stay outside the main dialysis payment. This could include drugs for heart disease, cancer, diabetes, or obesity if they are approved after December 31, 2025 and do not replace drugs already in the bundle.

How Modern Action helps you take action on H.R. 6214

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about H.R. 6214

What is H.R. 6214?

People on dialysis could get better access to some newer drugs and devices. Medicare would give extra payments for these products and add kidney screening to yearly wellness visits starting in 2026.

How do I support or oppose H.R. 6214?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about H.R. 6214?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

Can Modern Action explain H.R. 6214 before I act?

Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.